# Safety, Tolerability and PK Study of AK0529 in Healthy Human

> **NCT02297594** · PHASE1 · COMPLETED · sponsor: **Shanghai Ark Biopharmaceutical Co., Ltd.** · enrollment: 74 (actual)

## Conditions studied

- Respiratory Syncytial Virus Infections

## Interventions

- **DRUG:** AK0529
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02297594
- **Lead sponsor:** Shanghai Ark Biopharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10
- **Primary completion:** 2015-06
- **Final completion:** 2015-06
- **Target enrollment:** 74 (ACTUAL)
- **Last updated:** 2015-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02297594

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02297594, "Safety, Tolerability and PK Study of AK0529 in Healthy Human". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02297594. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*